LPL Financial LLC Buys 1,577 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

LPL Financial LLC lifted its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 60.1% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,199 shares of the biotechnology company’s stock after buying an additional 1,577 shares during the quarter. LPL Financial LLC’s holdings in Ascendis Pharma A/S were worth $578,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. American Century Companies Inc. lifted its stake in Ascendis Pharma A/S by 17.5% in the 4th quarter. American Century Companies Inc. now owns 407,294 shares of the biotechnology company’s stock worth $56,072,000 after purchasing an additional 60,548 shares in the last quarter. abrdn plc increased its holdings in shares of Ascendis Pharma A/S by 18.3% in the fourth quarter. abrdn plc now owns 187,180 shares of the biotechnology company’s stock worth $25,769,000 after purchasing an additional 28,967 shares during the last quarter. SG Americas Securities LLC lifted its position in shares of Ascendis Pharma A/S by 410.4% in the fourth quarter. SG Americas Securities LLC now owns 33,944 shares of the biotechnology company’s stock worth $4,673,000 after buying an additional 27,293 shares in the last quarter. New York State Common Retirement Fund boosted its stake in Ascendis Pharma A/S by 14.0% during the fourth quarter. New York State Common Retirement Fund now owns 204,482 shares of the biotechnology company’s stock valued at $28,151,000 after buying an additional 25,164 shares during the last quarter. Finally, Exome Asset Management LLC boosted its stake in Ascendis Pharma A/S by 119.2% during the third quarter. Exome Asset Management LLC now owns 43,849 shares of the biotechnology company’s stock valued at $6,547,000 after buying an additional 23,849 shares during the last quarter.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. Morgan Stanley set a $180.00 price objective on Ascendis Pharma A/S in a report on Tuesday, February 18th. JPMorgan Chase & Co. upped their price target on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an “overweight” rating in a research note on Tuesday, March 18th. Cantor Fitzgerald lifted their price objective on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 25th. Evercore ISI upped their target price on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an “outperform” rating in a research report on Tuesday, February 18th. Finally, Royal Bank of Canada started coverage on shares of Ascendis Pharma A/S in a report on Wednesday, April 16th. They issued an “outperform” rating and a $205.00 price target for the company. Two research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat, Ascendis Pharma A/S currently has an average rating of “Moderate Buy” and a consensus target price of $204.67.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ:ASND opened at $158.14 on Thursday. The business has a 50 day simple moving average of $153.31 and a two-hundred day simple moving average of $138.53. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $169.37. The firm has a market capitalization of $9.64 billion, a PE ratio of -22.27 and a beta of 0.54.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.64. Equities research analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.